Investors & Media

Corporate Profile

With its acquisition of Lung Therapeutics, Aileron is shifting its disease focus to orphan pulmonary and fibrosis indications. Aileron intends to advance Lung’s pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01, for loculated pleural effusion (LPE).

Data Provided by Refinitiv. Minimum 15 minutes delayed.

  • October 31, 2023
    Aileron Therapeutics Announces Acquisition of Lung Therapeutics
  • February 21, 2023
    Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
  • November 30, 2022
    Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements


  • October 31, 2023 at 1:30 PM EDT

    Aileron Therapeutics' Acquisition of Lung Therapeutics Conference Call

    Read More
  • September 29, 2022 at 3:30 PM EDT

    Ladenburg Thalmann 2022 Healthcare Conference

    Read More